235 related articles for article (PubMed ID: 28306392)
21. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
[TBL] [Abstract][Full Text] [Related]
22. LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.
Freiberg FJ; Brynskov T; Munk MR; Sørensen TL; Wolf S; Wirth MA; Becker M; Michels S
Retina; 2017 Dec; 37(12):2341-2346. PubMed ID: 28099318
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
[TBL] [Abstract][Full Text] [Related]
24. A calipers-free intravitreal anti-VEGF injection technique.
Oztas Z; Akkin C; Afrashi F; Selim S
Arq Bras Oftalmol; 2015; 78(2):133-4. PubMed ID: 25945539
[No Abstract] [Full Text] [Related]
25. Recovering Infectious HIV from Novel Syringe-Needle Combinations with Low Dead Space Volumes.
Abdala N; Patel A; Heimer R
AIDS Res Hum Retroviruses; 2016; 32(10-11):947-954. PubMed ID: 27548374
[TBL] [Abstract][Full Text] [Related]
26. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
27. Alternative technique for reducing compound waste during intravitreal injections.
Ribeiro JA; Messias A; Scott IU; Jorge R
Arq Bras Oftalmol; 2009; 72(5):641-4. PubMed ID: 20027401
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
[TBL] [Abstract][Full Text] [Related]
29. Accuracy, precision and repeatability in preparing the intravitreal dose with a 1.0-cc syringe.
Meyer CH; Liu Z; Brinkmann C; Rodrigues EB; Helb HM
Acta Ophthalmol; 2012 Mar; 90(2):e165-6. PubMed ID: 21470379
[No Abstract] [Full Text] [Related]
30. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
[TBL] [Abstract][Full Text] [Related]
31. Arteriosclerotic Changes after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Drugs in Patients with Exudative Age-Related Macular Degeneration.
Shiba T; Takahashi M; Yoshida I; Taniguchi H; Matsumoto T; Hori Y
Ophthalmologica; 2016; 235(4):225-32. PubMed ID: 27082736
[TBL] [Abstract][Full Text] [Related]
32. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
Xu Y; Tan CS
Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
[TBL] [Abstract][Full Text] [Related]
33. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
Forooghian F; Albiani DA; Kirker AW; Merkur AB
Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
[TBL] [Abstract][Full Text] [Related]
34. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab: safety of multiple doses from a single vial for consecutive patients.
Ng DS; Kwok AK; Chan CW; Li WW
Hong Kong Med J; 2012 Dec; 18(6):488-95. PubMed ID: 23223649
[TBL] [Abstract][Full Text] [Related]
36. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
[TBL] [Abstract][Full Text] [Related]
37. Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections.
Melo GB; Cruz NFSD; Emerson GG; Rezende FA; Meyer CH; Uchiyama S; Carpenter J; Shiroma HF; Farah ME; Maia M; Rodrigues EB
Prog Retin Eye Res; 2021 Jan; 80():100862. PubMed ID: 32311476
[TBL] [Abstract][Full Text] [Related]
38. Accuracy of intravitreal injection volume for aflibercept pre-filled syringe and BD Luer-Lok one-milliliter syringe.
Guest JM; Malbin B; Abrams G; Parendo A; Das S; Okeagu C; Ross BX; Kumar A; Lin X
Int J Retina Vitreous; 2022 Apr; 8(1):27. PubMed ID: 35382900
[TBL] [Abstract][Full Text] [Related]
39. Systemic Biodistribution and Intravitreal Pharmacokinetic Properties of Bevacizumab, Ranibizumab, and Aflibercept in a Nonhuman Primate Model.
Christoforidis JB; Briley K; Binzel K; Bhatia P; Wei L; Kumar K; Knopp MV
Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5636-5645. PubMed ID: 29094168
[TBL] [Abstract][Full Text] [Related]
40. Effect of intravitreal anti-VEGF on choroidal thickness in patients with diabetic macular edema using spectral domain OCT.
Kniggendorf VF; Novais EA; Kniggendorf SL; Xavier C; Cole ED; Regatieri CV
Arq Bras Oftalmol; 2016; 79(3):155-8. PubMed ID: 27463625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
